Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia

References

• Clarke, M. L.; Mackey, J. R.; Baldwin, S. A.; Young, J. D.; Cass, C. E. The Role of Membrane Transporters in Cellular Resistance to Anticancer Nucleoside Drugs. Cancer Treat. Res. 2002, 112, 27–47.
   PubMedGoogle Scholar
• Cao, H. X.; Miao, C. F.; Yan, L.; Tang, P.; Zhang, L. R.; Sun, L. Polymorphisms at microRNA Binding Sites of Ara-C and Anthracyclines-Metabolic Pathway Genes Are Associated with Outcome of Acute Myeloid Leukemia Patients. J. Transl. Med. 2017, 15, 235. DOI: 10.1186/s12967-017-1339-9.
   PubMed Web of Science ®Google Scholar
• Hummel-Eisenbeiss, J.; Hascher, A.; Hals, P. A.; Sandvold, M. L.; Muller-Tidow, C.; Lyko, F.; et al. The Role of Human Equilibrative Nucleoside Transporter 1 on the Cellular Transport of the DNA Methyltransferase Inhibitors 5-Azacytidine and CP-4200 in Human Leukemia Cells. Mol. Pharmacol. 2013, 84, 438–450. DOI: 10.1124/mol.113.086801.
   PubMed Web of Science ®Google Scholar
• Pastor-Anglada, M.; Perez-Torras, S. Emerging Roles of Nucleoside Transporters. Front. Pharmacol. 2018, 9, 606. DOI: 10.3389/fphar.2018.00606.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; van der Wilt, C. L.; van Moorsel, C. J.; Kroep, J. R.; Bergman, A. M.; Ackland, S. P. Basis for Effective Combination Cancer Chemotherapy with Antimetabolites. Pharmacol. Ther. 2000, 87, 227–253. DOI: 10.1016/S0163-7258(00)00086-3.
   PubMed Web of Science ®Google Scholar
• Tsukimoto, I.; Tawa, A.; Horibe, K.; Tabuchi, K.; Kigasawa, H.; Tsuchida, M.; et al. Risk-Stratified Therapy and the Intensive Use of Cytarabine Improves the Outcome in Childhood Acute Myeloid Leukemia: The AML99 Trial from the Japanese Childhood AML Cooperative Study Group. J. Clin. Oncol. 2009, 27, 4007–4013. DOI: 10.1200/JCO.2008.18.7948.
   PubMed Web of Science ®Google Scholar
• Murphy, T.; Yee, K. Cytarabine and Daunorubicin for the Treatment of Acute Myeloid Leukemia. Expert Opin. Pharmacother. 2017, 18, 1765–1780. DOI: 10.1080/14656566.2017.1391216.
   PubMed Web of Science ®Google Scholar
• Ciccolini, J.; Serdjebi, C.; Peters, G. J.; Giovannetti, E. Pharmacokinetics and Pharmacogenetics of Gemcitabine as a Mainstay in Adult and Pediatric Oncology: An EORTC-PAMM Perspective. Cancer Chemother. Pharmacol. 2016, 78, 1–12. DOI: 10.1007/s00280-016-3003-0.
   PubMed Web of Science ®Google Scholar
• Momparler, R. L. Optimization of Cytarabine (ARA-C) Therapy for Acute Myeloid Leukemia. Exp. Hematol. Oncol. 2013, 2, 20. DOI: 10.1186/2162-3619-2-20.
   PubMedGoogle Scholar
• Candelaria, M.; Corrales-Alfaro, C.; Gutierrez-Hernandez, O.; Diaz-Chavez, J.; Labardini-Mendez, J.; Vidal-Millan, S.; et al. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine. Chemotherapy 2016, 61, 313–318. DOI: 10.1159/000445370.
   PubMed Web of Science ®Google Scholar
• Rizzieri, D.; Vey, N.; Thomas, X.; Huguet-Rigal, F.; Schlenk, R. F.; Krauter, J.; et al. A Phase II Study of Elacytarabine in Combination with Idarubicin and of Human Equilibrative Nucleoside Transporter 1 Expression in Patients with Acute Myeloid Leukemia and Persistent Blasts after the First Induction Course. Leuk. Lymphoma 2014, 55, 2114–2119. DOI: 10.3109/10428194.2013.867489.
   PubMed Web of Science ®Google Scholar
• Huang, M.; Inukai, T.; Miyake, K.; Tanaka, Y.; Kagami, K.; Abe, M.; et al. Clofarabine Exerts Antileukemic Activity against Cytarabine-Resistant B-Cell Precursor Acute Lymphoblastic Leukemia with Low Deoxycytidine Kinase Expression. Cancer Med. 2018, 7, 1297–1316. DOI: 10.1002/cam4.1323.
   PubMed Web of Science ®Google Scholar
• Galmarini, C. M.; Thomas, X.; Calvo, F.; Rousselot, P.; El Jafaari, A.; Cros, E.; et al. Potential Mechanisms of Resistance to Cytarabine in AML Patients. Leuk. Res. 2002, 26, 621–629. DOI: 10.1016/S0145-2126(01)00184-9.
   PubMed Web of Science ®Google Scholar
• Galmarini, C. M.; Thomas, X.; Calvo, F.; Rousselot, P.; Rabilloud, M.; El Jaffari, A.; et al. In Vivo Mechanisms of Resistance to Cytarabine in Acute Myeloid Leukaemia. Br. J. Haematol. 2002, 117, 860–868. DOI: 10.1046/j.1365-2141.2002.03538.x.
   PubMed Web of Science ®Google Scholar
• Hubeek, I.; Stam, R. W.; Peters, G. J.; Broekhuizen, R.; Meijerink, J. P.; van Wering, E. R.; et al. The Human Equilibrative Nucleoside Transporter 1 Mediates in Vitro Cytarabine Sensitivity in Childhood Acute Myeloid Leukaemia. Br. J. Cancer 2005, 93, 1388–1394. DOI: 10.1038/sj.bjc.6602881.
   PubMed Web of Science ®Google Scholar
• Takagaki, K.; Katsuma, S.; Kaminishi, Y.; Horio, T.; Nakagawa, S.; Tanaka, T.; et al. Gene-Expression Profiling Reveals down-Regulation of Equilibrative Nucleoside Transporter 1 (ENT1) in Ara-C-Resistant CCRF-CEM-Derived Cells. J. Biochem. 2004, 136, 733–740. DOI: 10.1093/jb/mvh180.
   PubMed Web of Science ®Google Scholar
• Sarkar, M.; Han, T.; Damaraju, V.; Carpenter, P.; Cass, C. E.; Agarwal, R. P. Cytosine Arabinoside Affects Multiple Cellular Factors and Induces Drug Resistance in Human Lymphoid Cells. Biochem Pharmacol 2005, 70, 426–432. DOI: 10.1016/j.bcp.2005.05.014.
   PubMed Web of Science ®Google Scholar
• Macanas-Pirard, P.; Broekhuizen, R.; Gonzalez, A.; Oyanadel, C.; Ernst, D.; Garcia, P.; et al. Resistance of Leukemia Cells to Cytarabine Chemotherapy is Mediated by Bone Marrow Stroma, Involves Cell-Surface Equilibrative Nucleoside Transporter-1 Removal and Correlates with Patient Outcome. Oncotarget 2017, 8, 23073–23086. DOI: 10.18632/oncotarget.14981.
   PubMedGoogle Scholar
• Bergman, A. M.; Adema, A. D.; Balzarini, J.; Bruheim, S.; Fichtner, I.; Noordhuis, P.; et al. Antiproliferative Activity, Mechanism of Action and Oral Antitumor Activity of CP-4126, a Fatty Acid Derivative of Gemcitabine, in in Vitro and in Vivo Tumor Models. Invest New Drugs 2011, 29, 456–466. DOI: 10.1007/s10637-009-9377-7.
   PubMed Web of Science ®Google Scholar
• Stam, R. W.; den Boer, M. L.; Meijerink, J. P.; Ebus, M. E.; Peters, G. J.; Noordhuis, P.; et al. Differential mRNA Expression of Ara-C-Metabolizing Enzymes Explains Ara-C Sensitivity in MLL Gene-Rearranged Infant Acute Lymphoblastic Leukemia. Blood 2003, 101, 1270–1276. DOI: 10.1182/blood-2002-05-1600.
   PubMed Web of Science ®Google Scholar
• Catala, A.; Pastor-Anglada, M.; Caviedes-Cardenas, L.; Malatesta, R.; Rives, S.; Vega-Garcia, N.; et al. FLT3 is Implicated in Cytarabine Transport by Human Equilibrative Nucleoside Transporter 1 in Pediatric Acute Leukemia. Oncotarget 2016, 7, 49786–49799. DOI: 10.18632/oncotarget.10448.
   PubMedGoogle Scholar
• Winters, A. C.; Bernt, K. M. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front. Pediatr. 2017, 5, 4. DOI: 10.3389/fped.2017.00004.
   PubMed Web of Science ®Google Scholar
• Kim, J. H.; Lee, C.; Cheong, H. S.; Koh, Y.; Ahn, K. S.; Kim, H. L.; et al. SLC29A1 (ENT1) Polymorphisms and Outcome of Complete Remission in Acute Myeloid Leukemia. Cancer Chemother. Pharmacol. 2016, 78, 533–540. DOI: 10.1007/s00280-016-3103-x.
   PubMed Web of Science ®Google Scholar
• Amaki, J.; Onizuka, M.; Ohmachi, K.; Aoyama, Y.; Hara, R.; Ichiki, A.; et al. Single Nucleotide Polymorphisms of Cytarabine Metabolic Genes Influence Clinical Outcome in Acute Myeloid Leukemia Patients Receiving High-Dose Cytarabine Therapy. Int. J. Hematol. 2015, 101, 543–553. DOI: 10.1007/s12185-015-1766-4.
   PubMed Web of Science ®Google Scholar
• Kaspers, G. J.; Veerman, A. J.; Pieters, R.; Broekema, G. J.; Huismans, D. R.; Kazemier, K. M.; et al. Mononuclear Cells Contaminating Acute Lymphoblastic Leukaemic Samples Tested for Cellular Drug Resistance Using the Methyl-Thiazol-Tetrazolium Assay. Br. J. Cancer 1994, 70, 1047–1052. DOI: 10.1038/bjc.1994.446.
   PubMed Web of Science ®Google Scholar
• Hubeek, I., Giovannetti, E., Broekhuizen, A. J. F., Pastor-Anglada, M., Kaspers, G. J. L., Peters, G. J. Immunocytochemical Detection of hENT1 and hCNT1 in Normal Tissues, Lung Cancer Cell Lines and NSCLC Patient Samples. Nucleosides, Nucleotides & Nucleic Acids. 2008, 27, 787–793. DOI: 10.1080/15257770802145942.
   Google Scholar
• van Meerloo, J.; Kaspers, G. J.; Cloos, J. Cell Sensitivity Assays: The MTT Assay. Methods Mol. Biol. 2011, 731, 237–245. DOI: 10.1007/978-1-61779-080-5_20.
   PubMedGoogle Scholar
• Hubeek, I.; Kaspers, G. J.; Ossenkoppele, G. J.; Peters, G. J. Cytosine Arabinoside: Metabolism, Mechanisms of Resistance and Clinical Pharmacology. In Cancer Drug Discovery and Development: Deoxynucleoside Analogs in Cancer Therapy; Humana Press: Totowa, NJ, 2006; pp 119–151.
   Google Scholar
• Willemze, R.; Suciu, S.; Meloni, G.; Labar, B.; Marie, J. P.; Halkes, C. J.; et al. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger than Age 46 Years with Acute Myeloid Leukemia: results of the EORTC-GIMEMA AML-12 Trial. J. Clin. Oncol. 2014, 32, 219–228. DOI: 10.1200/JCO.2013.51.8571.
   PubMed Web of Science ®Google Scholar